Literature DB >> 21208879

Beneficial effects of treatment with anti-IgE antibodies (Omalizumab) in a patient with severe asthma and negative skin-prick test results.

Maarten van den Berge1, Ronald G Pauw, Jan G R de Monchy, Cees A van Minnen, Dirkje S Postma, Huib A M Kerstjens.   

Abstract

It is now well recognized that treatment with anti-IgE antibodies like omalizumab is a valuable option in patients with allergic asthma who remain symptomatic despite optimal treatment. To our knowledge, treatment with omalizumab in patients with nonallergic asthma has not been reported. We present and discuss a patient with severe asthma and elevated total IgE who had a negative radioallergosorbent (RAST) test result and a negative skin-prick test result; the patient showed a dramatic improvement with this treatment strategy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21208879     DOI: 10.1378/chest.10-0128

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  10 in total

Review 1.  Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.

Authors:  Christian Domingo
Journal:  Drugs       Date:  2017-10       Impact factor: 9.546

2.  Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs.

Authors:  R W Costello; D A Long; S Gaine; T Mc Donnell; J J Gilmartin; S J Lane
Journal:  Ir J Med Sci       Date:  2011-05-11       Impact factor: 1.568

Review 3.  Omalizumab for severe asthma: efficacy beyond the atopic patient?

Authors:  Christian Domingo
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

4.  Long-term benefits of omalizumab in a patient with severe non-allergic asthma.

Authors:  Francesco Menzella; Roberto Piro; Nicola Facciolongo; Claudia Castagnetti; Anna Simonazzi; Luigi Zucchi
Journal:  Allergy Asthma Clin Immunol       Date:  2011-05-24       Impact factor: 3.406

5.  Omalizumab: clinical use for the management of asthma.

Authors:  Neil C Thomson; Rekha Chaudhuri
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2012-06-12

Review 6.  Omalizumab for Severe Asthma: Beyond Allergic Asthma.

Authors:  C C Loureiro; L Amaral; J A Ferreira; R Lima; C Pardal; I Fernandes; L Semedo; A Arrobas
Journal:  Biomed Res Int       Date:  2018-09-17       Impact factor: 3.411

Review 7.  Which Child with Asthma is a Candidate for Biological Therapies?

Authors:  Andrew Bush
Journal:  J Clin Med       Date:  2020-04-24       Impact factor: 4.241

8.  A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma.

Authors:  E Suzanne Cohen; Claire L Dobson; Helena Käck; Bing Wang; Dorothy A Sims; Christopher O Lloyd; Elizabeth England; D Gareth Rees; Hongwei Guo; Sophia N Karagiannis; Siobhan O'Brien; Sofia Persdotter; Helena Ekdahl; Robin Butler; Feenagh Keyes; Sarah Oakley; Mats Carlsson; Emmanuel Briend; Trevor Wilkinson; Ian K Anderson; Phillip D Monk; Karin von Wachenfeldt; Per-Olof F Eriksson; Hannah J Gould; Tristan J Vaughan; Richard D May
Journal:  MAbs       Date:  2014-02-28       Impact factor: 5.857

9.  Against all odds: anti-IgE for intrinsic asthma?

Authors:  Marek Lommatzsch; Stephanie Korn; Roland Buhl; Johann Christian Virchow
Journal:  Thorax       Date:  2013-05-24       Impact factor: 9.139

Review 10.  Novel diagnostic approaches and biological therapeutics for intrinsic asthma.

Authors:  María Del Carmen Vennera; César Picado
Journal:  Int J Gen Med       Date:  2014-07-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.